Tools
Stock profile

Fresenius Medical Care AG (FMS)

FMS · Latest close $20.95 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$20.95
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

Fresenius Medical Care AG (FMS) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Latest close $20.95 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Pzena Investment Management · Dodge & Cox Funds — 2 tracked funds hold FMS. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

Sotera Health Co (SHC) · Progyny, Inc. (PGNY) · agilon health, inc. (AGL) · DAVITA INC. (DVA) · VIEMED HEALTHCARE, INC. (VMD) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Pzena Investment Management1.00%14,992,081TRIMMED (-0.4%) Q3 filed Oct 30
Dodge & Cox Funds0.05%3,826,910HELD Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -5.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

29.8519.802024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding233 of 8,857 filers
Long-only filers among them232
Change vs 2026 Q1+17 net · 226 entered · 209 exited
Shares reported, all filers42,460,920
Reported value, all filers$938.3M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryServices-Misc Health & Allied Services, NEC (SIC 8090)
Revenue · FY202519.6B EUR
Net income · FY20251.2B EUR
Total assets · FY202531.0B EUR
Shares outstanding279,288,885
Market cap (at latest close)$5.9B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.

Short interest

Shares short · Oct 15, 20263,957,374
Share of shares outstanding1.42%
Days to cover3.51

Shares short at recent settlements — Jul 31, 2026: 2.7M · Aug 14, 2026: 2.8M · Aug 31, 2026: 2.8M · Sep 15, 2026: 2.8M · Sep 30, 2026: 2.8M · Oct 15, 2026: 4.0M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 6K · Aug 31, 2026: 0 · Sep 15, 2026: 3K · Sep 30, 2026: 523 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Dec 20, 2023CLASSON ROLF ADirector5,714$119.2KDec 20, 2023SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Aug 24, 2026SCHEDULE 13D/A-7.7% (close Aug 25, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Aug 25, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 24, 2026Fresenius SE & Co. KGaASC 13D/A67,181,35825.6%Aug 20, 2026SEC filing
Jul 28, 2026BlackRock, Inc.SC 13G13,447,9145.0%Jun 30, 2026SEC filing
Mar 10, 2025Fresenius SE & Co. KGaASC 13D/A83,780,38228.6%Mar 6, 2025SEC filing
Mar 6, 2025Fresenius SE & Co. KGaASC 13D/A94,380,38232.2%Mar 4, 2025SEC filing
Feb 14, 2025HARRIS ASSOCIATES L PSC 13G/A11,717,5753.9%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Services-Misc Health & Allied Services, NEC (SIC 8090). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 12 Lobbying Disclosure Act filings named this company as client, 2023–2025; most common issues: Medicare/Medicaid (10), Health Issues (10).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Greenblatt Magic Formula — High earnings yield and high return on capital together

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Deep Value (Templeton) — Stocks that are cheap against both earnings and assets

· Neff Total Return Ratio — Growth plus dividends divided by P/E is high

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Key figures

· Greenblatt Magic Formula — Earnings yield: 12.8% · Return on capital: 43.6% · Combined rank: 32

· Cash Flow (FCF) — Latest FCF: $1.1B · FCF yield: 15.7% · Positive FCF years: 3

· Deep Value (Templeton) — P/E: 5.70 · P/B: 0.62 · Latest EPS: 4.06 · Dividend yield: 3.5%

· Neff Total Return Ratio — EPS growth: 2.9% · Dividend yield: 3.5% · P/E: 5.70 · Neff ratio: 1.13

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.80 · Operating cash flow: $2.1B · Net income: $1.2B

· Earnings Stability — Earnings variation (CV): 0.15 · Loss years (of 10): 0 · Latest net income: $1.2B

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together250.0%-0.6%+6.0%-6.7%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold FMS — ranked by lift, the co-holding pattern described in Methodology: Sotera Health Co (SHC) · Progyny, Inc. (PGNY) · agilon health, inc. (AGL) · DAVITA INC. (DVA) · VIEMED HEALTHCARE, INC. (VMD) · HCA Healthcare, Inc. (HCA) · Natera, Inc. (NTRA) · Guardant Health, Inc. (GH).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

No Form 8-K filings for this ticker in the index (Jan 2023 – present).

Related

Sotera Health Co (SHC) · Track Record: how the signals scored · Practice timing on FMS

One email a week: the week’s new filings and research. Subscribe free

← FMC  ·  FN →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.